Stock Taper 
VRXAW
$0.07
▲ UP 1.86% (0.00)
KEY STATISTICS
Market Cap$1.80 M
52w High$0.07
52w Low$0.07
Dividend Yield—
Frequency—
P/E—
Volume0
Shares Out.25.30M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Christoph Antz
ABOUT
SECTOR
Healthcare
WENT PUBLIC
June 10, 2026
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
47
PRICE
$0.07 ▲ UP 1.86% (+$0.00)About Veraxa Biotech AG
https://www.veraxa.com ↗Veraxa Biotech AG is a clinical-stage biopharmaceutical company developing next-generation antibody-based cancer therapies, including ADCs, founded on scientific breakthroughs from EMBL.
INDUSTRY
Biotechnology
A SERVICE VERAXA BIOTECH AG IS KNOWN FOR
Business Combination with VERAXA Biotech AG
Voyager Acquisition Corp. was a SPAC that merged with VERAXA Biotech AG, a developer of antibody-based cancer therapeutics, marking its primary goal of taking a private company public through this significant business combination.
